Business context and reporting period
CorVel Corporation (Nasdaq: CRVL) provides managed-care and medical cost-containment services, primarily for workers’ compensation, auto, and group health claims. Its offerings include claims and case management, medical bill review, provider networks, pharmacy, and directed care. The company reports one operating segment.
Period clarification: The supplied filing is CorVel’s Form 10-K for the fiscal year ended March 31, 2024—not a 2022 Q4 filing. It also includes unaudited quarterly results for fiscal 2024 and fiscal 2023.
Financial performance and position
| Metric | FY2024 | FY2023 | Change |
|---|---|---|---|
| Revenue | $795.3 million | $718.6 million | +10.7% |
| Gross profit | $171.7 million | $158.3 million | +8.5% |
| Income before taxes | $95.1 million | $84.6 million | +12.5% |
| Net income | $76.3 million | $66.4 million | +14.9% |
| Diluted EPS | $4.40 | $3.77 | +16.7% |
| Cash from operations | $99.2 million | $82.3 million | +$16.9 million |
- Gross margin was 21.6%, down from 22.0%; net margin was 9.6%, up from 9.2%. Cost of revenue rose 11.3%, including higher field staffing and wage costs. G&A increased 3.9%, mainly from corporate systems and software-development spending.
- Patient management revenue was $530.0 million and network solutions revenue was $265.3 million; each grew approximately 11%. Management cited higher TPA-related activity, increased bill-review revenue per bill, and greater activity with existing customers. New claims increased 4%.
- Cash and cash equivalents were $105.6 million at March 31, 2024, versus $71.3 million a year earlier. Working capital was $117.7 million, versus $75.9 million.
- Investing activities used $29.2 million, primarily for property and equipment, with increased software-development investment cited. Financing activities used $35.8 million, including $45.7 million for repurchases of 215,313 shares. The company reported virtually no interest-bearing debt for 33 years; the balance sheet includes $31.4 million of lease liabilities.
- Fiscal 2024 Q4 revenue was $207.2 million, gross profit $43.4 million, net income $19.5 million, and diluted EPS $1.12. In fiscal 2023 Q4, these were $185.4 million, $42.0 million, $18.2 million, and $1.04, respectively.
Changes, outlook, and notable items
- Annual revenue growth remained strong at 10.7%, while gross margin declined 0.4 percentage points. Net income and diluted EPS rose faster than revenue, supported by higher revenue, lower G&A growth relative to sales, and fewer diluted shares.
- Operating cash flow increased, though accounts receivable rose to $97.1 million from $81.0 million, including unbilled receivables of $42.4 million versus $26.6 million. The company reported a 39–44 day range for receivables as a proportion of average sales over the three fiscal years and expects DSO in the low-to-mid-40-day range.
- Management expects cash on hand and internally generated funds to cover expected requirements for at least the next 12 months and beyond. It gave no specific revenue or earnings guidance. Repurchases may continue, but can be reduced or suspended if cash flow or earnings weaken; no cash dividends are planned in the foreseeable future.
- Management said inflation did not materially affect fiscal 2024 revenue or net income, but warned that labor, benefits, leases, and competitive pricing pressures could affect future profitability. Longer-term risks include declining workers’ compensation claims, customer retention and outsourcing decisions, competition, regulatory changes, technology execution, cybersecurity, and recruiting and retaining staff.
- Ordinary-course litigation is described as not expected to result in material aggregate payments. The company reported no material cybersecurity incidents or costs in the last three fiscal years. It identified revenue estimation—including variable bill-review fees and unbilled directed-care services—as a critical audit matter. Auditors issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended period: this is FY2024, with the supplied Q4 comparison covering fiscal 2024 versus fiscal 2023.
- Assess whether revenue growth can continue if workers’ compensation claims decline or customers bring services in-house, and whether growth is concentrated in existing customers.
- Monitor gross margin, labor inflation, field headcount, software-development spending, and the conversion and collection of unbilled receivables.
- Review the company’s buyback pace and cash usage against operating cash flow, liquidity needs, and future investment or acquisition plans.
- Consider customer credit concentration: one customer represented at least 10% of accounts receivable at both year-ends, although no customer accounted for 10% or more of annual revenue.
- Review evolving healthcare, privacy, AI, and cybersecurity regulation, as well as the company’s contingent indemnification obligations; specific maximum amounts for some obligations are not stated.